Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#1
REVIEW
Rini Patadia, Thomas B Casale, John Fowler, Shiven Patel, Juan Carlos Cardet
INTRODUCTION: Asthma encompasses a spectrum of phenotypes often categorized into two groups- type 2 high (T2 high) and type 2 low (T2 low). T2 high includes atopic and eosinophilic presentations whereas T2 low is non-atopic, non-eosinophilic, and oft associated with neutrophilic inflammation. Eosinophilic asthma is often driven by IgE, IL-4, IL-5, and IL-13 and TSLP. This can lead to eosinophilic inflammatory response in the airways which in turn can be used as target for treatment. AREAS COVERED: The article will focus on biologic therapy that is currently being used in eosinophilic asthma management in mainly the adult population including clinical trials and co-morbidities that can be treated using the same biologics...
April 15, 2024: Expert Opinion on Biological Therapy
#2
JOURNAL ARTICLE
Amy McCarron, Sean Semple, Vivien Swanson, Colin Gillespie, Christine Braban, Heather D Price
BACKGROUND: Exposure to air pollution can exacerbate asthma with immediate and long-term health consequences. Behaviour changes can reduce exposure to air pollution, yet its 'invisible' nature often leaves individuals unaware of their exposure, complicating the identification of appropriate behaviour modifications. Moreover, making health behaviour changes can be challenging, necessitating additional support from healthcare professionals. OBJECTIVE: This pilot study used personal exposure monitoring, data feedback, and co-developed behaviour change interventions with individuals with asthma, with the goal of reducing personal exposure to PM2...
April 12, 2024: Journal of Exposure Science & Environmental Epidemiology
#3
JOURNAL ARTICLE
Lee Hatter, Mark Holliday, Allie Eathorne, Pepa Bruce, Ian D Pavord, Helen K Reddel, Robert J Hancox, Alberto Papi, Mark Weatherall, Richard Beasley
INTRODUCTION: The use of pressurised metered-dose inhalers (pMDIs) and asthma exacerbations necessitating healthcare reviews contribute substantially to the global carbon footprint of healthcare. It is possible that a reduction in carbon footprint could be achieved by switching patients with mild asthma from salbutamol pMDI reliever therapy to inhaled corticosteroid-formoterol dry powder inhaler (DPI) reliever therapy, as recommended by the Global Initiative for Asthma (GINA). METHODS: This post hoc analysis included all 668 adult participants in the Novel START trial, who were randomised 1:1:1 to treatment with: as-needed budesonide-formoterol DPI, as-needed salbutamol pMDI, or maintenance budesonide DPI plus as-needed salbutamol pMDI...
April 12, 2024: European Respiratory Journal
#4
JOURNAL ARTICLE
Renaud Louis, Mare Sabbe, Nicolas Bougard, Anne-Noëlle Frix, Florence Schleich
Severe asthma often features a T2 high profile regulated by cytokines such as interleukins IL-4, IL-5 and IL-13. Dupilumab (Dupixent®) is humanized monoclonal antibody directed against the α subunit of the receptor for IL-4 and IL-13. Here we summarise the immunogical background of severe asthma which supports the use of dupilumab and the pivotal randomised controlled trials which have established the efficacy of dupilumab in treating people with severe asthma. Dupilumab reduces the exacerbation rate, has corticosteroids sparing effect, provides sustained improvement in expiratory flow rates and improved asthma control and quality of life with a reassuring safety profile...
April 2024: Revue Médicale de Liège
#5
JOURNAL ARTICLE
Justin J Y Kim, Liz Dennett, Maria B Ospina, Anne Hicks, Harissios Vliagoftis, Adil Adatia
PURPOSE: Immunoglobulin replacement therapy is a standard treatment for patients with antibody production deficiencies, which is of interest in patients with chronic obstructive pulmonary disease (COPD). This systematic review, registered with PROSPERO (CRD42021281118), assessed the current literature regarding immunoglobulin replacement therapy on COPD clinical outcomes in patients with low immunoglobulin G (IgG) serum concentrations. METHODS: Literature searches conducted from inception to August 23, 2021, in databases including MEDLINE, EMBASE, and CINAHL...
April 10, 2024: Allergy, Asthma, and Clinical Immunology
#6
JOURNAL ARTICLE
Christopher McPherson, Christine R Lockowitz, Jason G Newland
Respiratory syncytial virus (RSV) is the leading cause of hospitalization in infancy in the United States. Nearly all infants are infected by 2 years of age, with bronchiolitis requiring hospitalization often occurring in previously healthy children and long-term consequences of severe disease including delayed speech development and asthma. Incomplete passage of maternal immunity and a high degree of genetic variability within the virus contribute to morbidity and have also prevented successful neonatal vaccine development...
April 1, 2024: Neonatal Network: NN
#7
REVIEW
Ulrike Förster-Ruhrmann, Heidi Olze
BACKGROUND: Nonsteroidal anti-inflammatory drug-exacerbated respiratory disease (N-ERD) is often characterized by a severe course of chronic rhinosinusitis with nasal polyps (CRSwNP), comorbid asthma, and NSAID hypersensitivity. The gold standard for N-ERD diagnosis is challenge with acetylsalicylic acid (ASA). In expert recommendations, the diagnosis of N-ERD is established based on a plausible positive history of NSAID hypersensitivity and CRSwNP with asthma. OBJECTIVE: The following review describes the performance of ASA challenges and their sensitivity and specificity...
April 10, 2024: HNO
#8
JOURNAL ARTICLE
Tasmin Barry, Mark Holliday, Jenny Sparks, Rowan Biggs, Atalie Colman, Rebekah Lamb, Karen Oldfield, Nick Shortt, Kyley Kerse, John Martindale, Allie Eathorne, Michaela Walton, Bianca Black, Matire Harwood, Pepa Bruce, Ruth Semprini, Andrew Bush, Louise Fleming, Catherine A Byrnes, David McNamara, Lee Hatter, Stuart R Dalziel, Mark Weatherall, Richard Beasley
BACKGROUND: Asthma is the most common chronic childhood respiratory condition globally. Inhaled corticosteroid (ICS)-formoterol reliever-based regimens reduce the risk of asthma exacerbations compared with conventional short-acting β2 -agonist (SABA) reliever-based regimens in adults and adolescents. The current limited evidence for anti-inflammatory reliever therapy in children means it is unknown whether these findings are also applicable to children. High-quality randomised controlled trials (RCTs) are needed...
March 2024: ERJ Open Research
#9
JOURNAL ARTICLE
Troels Yndigegn, Bertil Lindahl, Katarina Mars, Joakim Alfredsson, Jocelyne Benatar, Lisa Brandin, David Erlinge, Ola Hallen, Claes Held, Patrik Hjalmarsson, Pelle Johansson, Patric Karlström, Thomas Kellerth, Toomas Marandi, Annica Ravn-Fischer, Johan Sundström, Ollie Östlund, Robin Hofmann, Tomas Jernberg
BACKGROUND: Most trials that have shown a benefit of beta-blocker treatment after myocardial infarction included patients with large myocardial infarctions and were conducted in an era before modern biomarker-based diagnosis of myocardial infarction and treatment with percutaneous coronary intervention, antithrombotic agents, high-intensity statins, and renin-angiotensin-aldosterone system antagonists. METHODS: In a parallel-group, open-label trial performed at 45 centers in Sweden, Estonia, and New Zealand, we randomly assigned patients with an acute myocardial infarction who had undergone coronary angiography and had a left ventricular ejection fraction of at least 50% to receive either long-term treatment with a beta-blocker (metoprolol or bisoprolol) or no beta-blocker treatment...
April 7, 2024: New England Journal of Medicine
#10
JOURNAL ARTICLE
Donna-Marie Palakiko, Joanne R Loos
No abstract text is available yet for this article.
April 2024: Hawai'i journal of health & social welfare
#11
REVIEW
Xiaoxu Li, Tingchao He, Sufang Duan, Jinghong Liang, Gang Feng, Fang Li, Zhenyu Shen, Wenhui Ye, Biao Liu, Bibo Jiang, Yujing Chen, Nan Liu, Ignatius Man-Yau Szeto, Li Cai
Despite the widely recommended usage of partially or extensively hydrolyzed milk protein formula (PHF or EHF) for preventing allergic diseases (ADs), clinical studies have been inconclusive regarding their efficacy compared with cow's milk formula (CMF) or breast milk (BM). We aimed to systematically evaluate the effects of PHF or EHF versus CMF or BM on the risk of ADs (cow's milk allergy, allergic rhinitis, eczema, asthma, wheeze, food allergy, and sensitization) in children. We searched PubMed, Embase, Cochrane Library, and Web of Science for clinical trials published from inception to October 21st, 2022...
April 3, 2024: Advances in Nutrition
#12
JOURNAL ARTICLE
Nabila Tabassum, Kazi Selim Anwar, Probir Kumar Sarkar, A R M Luthful Kabir, Md Abid Hossain Mollah, Dipa Saha, Md Jahangir Alam, Mohammod Jobayer Chisti
Objectives. To evaluate the interaction between childhood asthma and S. 25(OH) cholecalciferol among Bangladeshi children. Methods. This case control study was conducted in child asthma clinic, Bangladesh Shishu Hospital Institute during March-August 2021. Comparison was made between clinically-diagnosed (following GINA guideline) asthmatic children (2-12 years-old) (cases = 87) and age and sex-matched children having no respiratory illness (controls = 90) using SPSS' (Statistical Package for Social Science, V...
2024: Global Pediatric Health
#13
JOURNAL ARTICLE
David J Jackson, Girolamo Pelaia, Benjamin Emmanuel, Trung N Tran, David Cohen, Vivian H Shih, Anat Shavit, Douglas Arbetter, Rohit Katial, Adrian Paul J Rabe, Esther Garcia Gil, Marisa Pardal, Javier Nuevo, Michael Watt, Silvia Boarino, Sheena Kayaniyil, Cláudia Chaves Loureiro, Alicia Padilla-Galo, Parameswaran Nair
BACKGROUND: Pivotal Phase 3 trials and real-world studies have demonstrated benralizumab's overall efficacy and safety in severe eosinophilic asthma (SEA). Additional large-cohort data are needed to confirm its real-world effectiveness in SEA according to previous biologic use and key baseline characteristics important for treatment selection. METHODS: XALOC-1 is a large, multinational, retrospective, observational, real-world study programme of benralizumab in adults with SEA...
April 4, 2024: European Respiratory Journal
#14
REVIEW
Islam E Alkhazali, Ahmad Alrawashdeh, Mohd Hashairi Fauzi, Nik Hisamuddin Nik Ab Rahman
INTRODUCTION: The quality of healthcare for pediatric asthma patients in the emergency department (ED) is of growing importance. This systematic review aimed to identify and describe existing quality indicators (QIs) designed for use in the ED for pediatric asthma care. METHODS: We systematically searched three main electronic databases in May 2023 for all English-language qualitative and quantitative publications that suggested or described at least one QI related to pediatric asthma care in the ED...
2024: Archives of Academic Emergency Medicine
#15
JOURNAL ARTICLE
Kefang Lai, Dejun Sun, Ranran Dai, Ronnie Samoro, Hae-Sim Park, Annika Åstrand, David Cohen, Maria Jison, Vivian H Shih, Viktoria Werkström, Yuhui Yao, Yajuan Zhang, Wenying Zheng, Nanshan Zhong, Albay Albert, Bo Jianping, Chen Bi, Chen Lijun, Chen Mei, Chen Min, Chen Ping, Chen Zhimin, Chian Chih-Feng, Cho You Sook, Fu Xiuhua, Gao Xiwen, Gu Wei, Han Wei, Han Zhihai, Hu Xi Wei, Huang Kewu, Huang Mao, Isidro Marie Grace Dawn, Jeong Inbeom, Jiang Luning, Jiang Mingyan, Jiang Shanping, Jin Meiling, Kang Jian, Kim Jin Woo, Kim Sang-Ha, Kuang Jiulong, Kuo Ping-Hung, Li Jie, Li Manxiang, Li Minjing, Li Ruoran, Li Wen, Li Xianhua, Li Yanming, Lim Seong Yong, Liu Chuanhe, Liu Chuntao, Liu Jing, Liu Xiaoxia, Lu Huiyu, Luo Zhuang, Ma Shengxi, Mao Liangping, Min Kyung Hoon, Mu Lin, Park Choon-Sik, Park Hae Sim, Park Hye-Kyung, Park Jung-Won, Perng Diahn-Warng, Samoro Ronnie, Shi Guochao, Sun Debin, Sun Dejun, Wang Chun-Hua, Wang Guangfa, Wang Limin, Wang Xuefen, Wang Yan, Wei Liping, Wu Haihong, Xiao Yi, Xiao Zuke, Xie Canmao, Xu Jin-Fu, Xu Xingxiang, Xu Xiyuan, Yan Jianping, Yang Hongzhong, Yoon Ho Joo, Yu Wencheng, Zhang Jin, Zhang Longju, Zhang Min, Zhang Wei, Zhao Jianping, Zhao Ziwen, Zhu Xiaoli, Zhu Yingqun
BACKGROUND: Benralizumab is indicated as add-on therapy in patients with uncontrolled, severe eosinophilic asthma; it has not yet been evaluated in a large Asian population with asthma in a clinical trial. OBJECTIVE: To evaluate the efficacy and safety of benralizumab in patients with severe asthma in Asia. METHODS: MIRACLE (NCT03186209) was a randomized, Phase 3 study in China, South Korea, and the Philippines. Patients aged 12-75 years with severe asthma receiving medium-to-high-dose inhaled corticosteroid/long-acting β2 -agonists, stratified (2:1) by baseline blood eosinophil count (bEOS) (≥300/μL; <300/μL), were randomized (1:1) to benralizumab 30 mg or placebo...
April 1, 2024: Respiratory Medicine
#16
REVIEW
Rohit Goyal, Amrit K Kamboj, Diana L Snyder
Eosinophilic esophagitis (EoE) is a chronic and progressive immune-mediated esophageal disorder. Given its increasing incidence, it is now a leading cause of dysphagia and food impaction in the United States. Eosinophilic esophagitis is most common in adult White men and has a high concurrence rate with other atopic conditions like allergic rhinitis, bronchial asthma, and eczema. The initial presentation includes symptoms of esophageal dysfunction, classically solid-food dysphagia. Without treatment, inflammation can progress to fibrosis with the formation of strictures, leading to complications such as food impaction...
April 2024: Mayo Clinic Proceedings
#17
RANDOMIZED CONTROLLED TRIAL
Rebecca K Vinding, Astrid Sevelsted, David Horner, Nilofar Vahman, Lotte Lauritzen, Casper P Hagen, Bo Chawes, Jakob Stokholm, Klaus Bønnelykke
BACKGROUND: We previously reported that children of mothers who received fish oil supplementation during pregnancy had higher body mass index [BMI (in kg/m2 )] at 6 y of age as well as a concomitant increase in fat-, muscle, and bone mass, but no difference in fat percentage. OBJECTIVES: Here, we report follow-up at age 10 y including assessment of metabolic health. METHODS: This is a follow-up analysis of a randomized clinical trial conducted among 736 pregnant females and their offspring participating in the Copenhagen Prospective Studies on Asthma in Childhood mother-child cohort...
April 2024: American Journal of Clinical Nutrition
#18
Yuping Xiang, Tianhui Luo, Xinyang Chen, Huanhuan Zhang, Ling Zeng
BACKGROUND: Asthma is a common chronic respiratory disease in children. Alongside pharmacological interventions, inspiratory muscle training (IMT) emerges as a complementary therapeutic approach for asthma management. However, the extent of its efficacy in pediatric populations remains uncertain when compared to its benefits in adults. This systematic review aims to evaluate the effectiveness of IMT with threshold loading in children with asthma. METHODS: Randomized controlled trials (RCTs) evaluating the efficacy of inspiratory muscle training in pediatric asthma patients were identified through June 2023 across various literature databases, including PubMed, Embase, Cochrane Central Register of Controlled Trials (CENTRAL), Cumulative Index to Nursing and Allied Health Literature (CINAL), Web of Science, China Knowledge Resource Integrated Database (CNKI), Wei Pu Database, Wan Fang Database, and Chinese Biomedical Database (CBM)...
2024: Frontiers in Pediatrics
#19
JOURNAL ARTICLE
Danny Darmawan, Iris Rengganis, Cleopas Martin Rumende, Hamzah Shatri, Soekamto Koesnoe, Yogi Umbarawan, Rudi Putranto, Sally Aman Nasution
BACKGROUND: Asthma is a disease characterized by chronic airway inflammation, however one-third of asthmatic cases did not respond adequately. Inhaled magnesium has been proposed as a treatment for unresponsive asthma cases. However, its role remains controversial. This review evaluates the effectiveness and safety of nebulized magnesium compared to standard therapy (Beta Agonist, Anticholinergic, Corticosteroid) in adults with acute asthma attacks. METHODS: The protocol has been registered in PROSPERO...
January 2024: Acta Medica Indonesiana
#20
REVIEW
Phyllis X L Gan, Shanshan Zhang, W S Fred Wong
Metabolic reprogramming underlies the etiology and pathophysiology of respiratory diseases such as asthma, idiopathic pulmonary fibrosis (IPF), and chronic obstructive pulmonary disease (COPD). The dysregulated cellular activities driving airway inflammation and remodelling in these diseases have reportedly been linked to aberrant shifts in energy-producing metabolic pathways: glycolysis and oxidative phosphorylation (OXPHOS). The rewiring of glycolysis and OXPHOS accompanying the therapeutic effects of many clinical compounds and natural products in asthma, IPF, and COPD, supports targeting metabolism as a therapeutic approach for respiratory diseases...
March 30, 2024: Biochemical Pharmacology
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
